Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) saw its price target increased by Leerink Partners from €113.00 to €120.00, while the firm maintained an Outperform rating on the company's shares. Currently ...

Sanofi (NASDAQ:SNY) announced on Thursday that it plans to repurchase €5 billion ($5.21 billion) worth of shares this year and may take a more active approach to acquisitions in the near term. The ...

Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in ...

(RTTNews) - Sanofi's Consumer Healthcare division ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

(RTTNews) - Sanofi (SNYNF, SNY ... the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...

$690,000 of SANOFI US SERVICES INC lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues related to Pharmacy Benefit ...

Sanofi SNY announced that the European Commission (“EC”) has granted marketing authorization to expand the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa ...

Deutsche Bank has upgraded Sanofi (NASDAQ:SNY) to hold from sell, citing the company's Q4 earnings report. The investment ...

Geneos Wealth Management Inc. decreased its position in Sanofi (NASDAQ:SNY – Free Report) by 2.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 10,223 shares of the company’s stock ...

(RTTNews) - French drug major Sanofi (SNY) announced Monday that its ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study ...